AI Drug Firm Insilico Soars In IPO, But The Real Test Is Ahead
Insilico Medicine, an AI-powered drug discovery company, saw its shares surge nearly 25% in its Hong Kong IPO. The listing, backed by giants like Eli Lilly and Tencent, values the firm at over $2 billion. Now, it has to prove its technology can actually get a drug to market.